Badania naukowe

Informacje podstawowe na temat SIBO, IMO

1. Achufusi T. i wsp., Small Intestinal Bacterial Overgrowth: Comprehensive Review of Diagnosis, Prevention, and Treatment Methods, 2020
2. Adamska A. i wsp. Small intestinal bacterial overgrowth in adult patients with type 1 diabetes: its prevalence and relationship with metabolic control and the presence of chronic complications of the disease, Pol. Arch. Med. Wewn., 2016
3. Aragon M. i wsp., Irritable Bowel Syndrome and Endometriosis: Twins in Disguise, Greenvile Health System, 2017
4. Borghini R. i wsp., Irritable Bowel Syndrome-Like Disorders in Endometriosis: Prevelence of Nickiel Sensivity and Effects of a Low-Nickel Diet. An Open-Label Pilot Study, Nutrients, 2020
5. Bouchoucha M. et wsp., Metformin and digestive disorders. Diabetes Metab. 2011
6. Brechmann T. i wsp., Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study, World J Gastroenterol., 2017
7. Brechmann T., Sperlbaum A., Schmiegel W., Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study, WJG, 2017
8. Bristol Stool Form Scale, Rome Fundation, https://theromefoundation.org/rome-iv/rome-iv-criteria/ (dostęp 3.01.2023 r.)
9. Bryrup Th. Et wsp., Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study, Diabetologia, 2019
10. Chen B. i wsp., Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis, 2018

11. Collins S. i wsp., The interplay between the intestinal microbiota and the brain, Nature Reviews Microbiology, 2012
12. Crowell M., Role of serotonin in the pathophysiology of the irritable bowel syndrome, Br J Pharmacol., 2004
13. Erdrich S. i wsp., Determining the association between fibromyalgia, the gut microbiome and its biomarkers: A systematic review, BMC Musculoskeletal Disorders, 2020
14. Fujimori S., What are the effect of proton pump inhibitors on the small intestine? World J Gastronterol, 2015
15. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV, Functional GI Overview, 2016
16. Gaci N. i wsp., Archaea and the human gut: New beginning of an old story , World Journal of Gastroenterology, 2014
17. Gatta L., Scarpignato C., Systematic review with meta‐analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth, Aliment Pharmacol Ther, 2017
18. Grzymisławski M. (red), Dietetyka kliniczna, Wydanie I, Warszawa, PZWL, 2019
19. Gupta A. I wsp., Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy, 2010
20. Henderson B., Levothyroxine Sodium Oral Solution Normalizes Thyroid Function in a Patient with Hashimoto’s Disease, Gastritis, Diabetic Gastroparesis, and Small Intestinal Bacterial Overgrowth (SIBO), International Medical Case Reports Journal, 2021
21. Hutyra T., Iwańczak B., Small Bowel Bacterial Overgrowth – Pathogenesis, Symptoms, Diagnosis and Treatment, Adv Clin Exp Med, 2009
22. Iizuka M. i wsp., Elemental diet modulates the growth of Clostridium difficile in the gut flora, 2004
23. Janczy A. i wsp., Endotoksemia i zaburzenia bariery jelitowej towarzyszące nadwadze i otyłości, 2019
24. Kacik J., Wawrzyniak A., Radkowska M., Kalicki B., Objawy pseudoalergii a zaburzenia metabolizmu histaminy, Pediatr Med Rodz , 2016

25. Konrad P. i wsp., Ocena czynności tarczycy u osób z zespołem przerostu bakteryjnego jelita cienkiego, Pol Merkur Lekarski, 2018
26. Krauss H., Gibas-Dorna M., Fizjologia człowieka, Warszawa, PZWL, 2022
27. Li-hui Y. i wsp, Association between small intestinal bacterial overgrowth and beta-cell function of type 2 diabetes, J Int Med Res., 2020
28. Litwinowicz M. et wsp., Cukrzyca a zaburzenia ze strony przewodu pokarmowego ze szczególnym uwzględnieniem zespołu rozrostu bakteryjnego, ViaMedica, 2013
29. Lo W.K., Chan W.W., Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol., 2013
30. Meurs-Szojda M. i wsp., Irritable bowel syndrome and chronic constipation in patients with endometriosis, Colorectal Disease, 2010
31. Mizerski G. et wsp., Wpływ postaci metforminy na częstośc występowania objawów niepożądanych, Forum Medycyny Rodzinnaj, 2020
32. Morozińska-Gogol J., Parazytologia medyczna. Kompendium, PZWL, 2022
33. niepublikowane materiały szkoleniowe Nutribiota 2022
34. Niepublikowane materiały szkoleniowe Online FODMAP and IBS Training for Dietetitians, Monash University, 2019
35. Niepublikowane materiały szkoleniowe SIBO SOS 2020, wykłady Siebecker A., Pimentel M.
36. Olszewska J., Jagusztyn-Krynicka E., Human microbiome project – microflora jelit oraz jej wpływ na fizjologię i zdrowie człowieka, Post. Mikrobiol., 2012
37. Panasiuk A. (red.), Encefalopatia wątrobowa, PZWL, Wydanie I, Warszawa 2016

38. Panasiuk A. (red), Choroby infekcyjne przewodu pokarmowego, Wydanie I, Warszawa, PZWL, 2021
39. Panasiuk A., Kowalińska J., Mikrobiota przewodu pokarmowego, Wydanie I, Warszawa, PZWL, 2019
40. Pande C. i wsp., Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease, 2009

41. Pande C., Kumar A., Sarin S.K., Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease
42. Panek-Jeziorna M., Mulak A., Rola kwasów żółciowych w patogenezie chorób jelit, Postępy higieny i medycyny doświadczalnej, 2017
43. Patil A., Link between hypothyroidism and small intestinal bacterial overgrowth, Indian Journal of Endocrynology and Metabolism, 2014
44. Pietrzak A. i wsp., Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego, Gastroenterology Review, 2018
45. Pietrzak A. i wsp., Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego, Gastroenterology Rev, 2018

46. Pimentel M. i wsp., A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing, Ann Rheum Dis, 2004
47. Pimentel M. i wsp., ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth, Am J Gastroenterol., 2020
48. Pimentel M. i wsp., Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity, Am J Physiol Gastrointest Liver Physiol, 2005
49. red. Ponikowska B., Fizjologia człowieka zintegrowane podejście, PZWL, Wydanie I, Warszawa 2019
50. Satish S C Rao, Jigar Bhagatwala, Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management, 2019

51. Shah A. i wsp., Systematic review with meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease, Aliment Pharmacol Ther., 2019
52. Skonieczna-Żydecka K. i wsp., Microbiome-The Missing Link in the Gut-Brain Axis: Focus on Its Role in Gastrointestinal and Mental Health, J Clin Med., 2018
53. Stachowska E. (red), Żywienie w zaburzeniach mikrobioty jelitowej, Wydanie I, Warszawa, PZWL, 2021
54. Strandwitz P., Neurotransmitter modulation by the gut microbiota, Brain Res., 2018
55. Suri J. i wsp., Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit, Medicine, 2018
56. Szpunar-Radkowska H., Dieta w endometriozie, PZWL, Wydanie I, Warszawa 2021
57. The human gut microbiota, JRC Technical Reports, Publication Office of the European Union, 2018
58. Traczyk W., Fizjologia człowieka w zarysie, Wyd. VIII, Warszawa, PZWL Wydawnictwo Lekarskie, 2020

LECZENIE SIBO, IMO

1. Barba E, Accarino A, Azpiroz F. Correction of abdominal distension by biofeedback-guided control of abdominothoracic muscular activity in a randomized, placebo-controlled trial. Clin Gastroenterol Hepatol 2017;12:1922–1929.
2. Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018;113:735–745.
3. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled trials. Aliment Pharmacol Ther 2009; 29:329–341
4. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303
5. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy. Barshop K, Staller K. Ther Adv Chronic Dis. 2017 Nov;8(11):153-160
6. Etzioni D.A., Mack T., Beart R.W. Jr, Kaiser A.M. Diverticulitis in the United States: 1998−2005: changing patterns of disease and treatment. An. Surg. 2009; 249: 210−217.
7. Gwee K, Ghoshal U, Chen M. Irritable bowel syndrome in Asia: pathogenesis, natural history, epidemiology and management. J Gastroenterol Hepatol 2018; 33: 99-110
8. Interna. Medycyna Praktyczna, Kraków 2022
9. Julia A. Barman Balfour, Karen L. Goa and Caroline M. Perry, Alosetron, Adis International Limited, Auckland, New Zealand, New Drug Profile Published: 10 October 2012
10. Ke M, Tack J, Quigley EMM, et al. Effect of prucalopride in the treatment of chronic constipation in Asian and non-Asian women: a pooled analysis of 4 randomized, placebocontrolled trials. J Neurogastroenterol Motil 2014;20:458–468.
11. Lauritano E.C., Gabrielli M., Scarpellini E. i wsp.: Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am. J. Gastroenterol., 2008; 103: 2031–2035
12. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365:527–536.
13. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Toljan K, Vrooman B. Med Sci (Basel). 2018 Sep 21;6(4):82.
14. Management of Chronic Abdominal Distension and Bloating. Lacy BE, Cangemi D, Vazquez-Roque M. Clin Gastroenterol Hepatol. 2021 Feb;19(2):219-231.e1.
15. Mark Pimentel, Director GI Motility Program, Cedars-Sinai Medical Center, Review of rifaximin as treatment for SIBO and IBS, Drug Evaluations, Pages 349-358 | Published online: 09 May 2009
16. Martinez-Vazquez MA, Vazquez-Elizondo G, GonzalezGonzalez JA, et al. Effect of antispasmodic agents, alone or incombination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012; 77:82–90.
17. Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821–828.
18. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–1666.
19. Opipramol (Insidon) in the treatment of somatoform disorders H J Freyberger 1, H J Grabe, W Maier, A Janca, K D Stoll PMID: 9922924
20. Pietrzak A., Skrzydło-Radomańska B., Mulak A., Lipiński M., Małecka-Panas E., Reguła J., Rydzewska G. Guidelines on the management of irritable bowel syndrome. Gastroenterology Rev 2018; 13 (4): 167–196.
21. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506
22. Pittayanon R, Yuan Y, Bollegala N, et al. Prokinetics for functional dyspepsia: a systematic review and meta-analysis of randomized controlled trials. Am J Gastroenterol 2019; 114:233–243.
23. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355–361.
24. Psychopharmacologic Therapies for Irritable Bowel Syndrome. Törnblom H, Drossman DA. Gastroenterol Clin North Am. 2021 Sep;50(3):655-669.
25. Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020 Oct;159(4):1526-1532.
26. Rao SSC, Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin Transl Gastroenterol. 2019 Oct;10(10):e00078
27. Rao SSC, Rehman A, Yu S, et al. Brain fogginess, gas and bloating: A link between SIBO, probiotics and metabolic acidosis. Clin Transl Gastroenterol 2018;9:162
28. Rezaie A. Heimanson Z. McCallum R.et al. Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2019; 114: 1886-1893
29. Saito YA, Almazar AE, Tilkes KE, et al. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 2019;49(4): 389–97.
30. Scarpellini E., Giorgio V., Gabrielli M. i wsp.: Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur. Rev. Med. Pharmacol. Sci., 2013; 17 (10): 1314–1320
31. Schmulson MJ, Chiu-Ugalde J, Sáez-Ríos A, et al. Efficacy of the combination of pinaverium bromide 100 mg plus simethicone 300 mg in abdominal pain and bloating in irritable bowel syndrome: a randomized, placebo-controlled trial. J Clin Gastroenterol 2020;54:e30–e39.
32. Shah SC, Day LW, Somsouk M, et al. Meta-analysis: Antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013;38: 925–34.
33. Small Intestinal Bacterial Overgrowth: How to Diagnose and Treat (and Then Treat Again) Brian Ginnebaugh 1, William D Chey 2, Richard Saad 2 PMID: 32718571
34. Stotzer PO, Blomberg L, Conway PL, et al. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD. Scand J Infect Dis 1996;28:615–9.
35. Tahan S., Melli L.C., Mello C.S., Rodrigues M.S., Bezerra Filho H., de Morais M.B.: Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. J. Pediatr. Gastroenterol. Nutr., 2013; 57 (3): 316–318
36. Vasant D.H., Paine P.A., Black C.J. i wsp.: British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut, 2021;70;1214-1240
37. Von Armin U, Peitz U, Gundermann KJ, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007;102:1268–1275.
38. Yao CK, Barrett JS, Philpott H, et al. Poor predictive value of breath hydrogen response for probiotic effects in IBS. J Gastroenterol Hepatol 2015;30:1731–9.
39. Zhong C, Qu C,Wang B, et al. Probiotics for preventing and treating small intestinal bacterial overgrowth: A meta-analysis and systematic review of current evidence. J Clin Gastroenterol 2017;51:300–11.

Diagnostyka różnicowa

1. Adam M.G., Beyer G., Christiansen N. i wsp.: Identification and validation of a multivariable prediction model based on blood plasma and serum metabolomics for the distinction of chronic pancreatitis subjects from non-pancreas disease control subjects. Gut, 2021; 70: 2150–2158
2. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Barkun AN, Love J, Gould M, Pluta H, Steinhart H. Can J Gastroenterol. 2013 Nov;27(11):653-9
3. Etzioni D.A., Mack T., Beart R.W. Jr, Kaiser A.M. Diverticulitis in the United States: 1998−2005: changing patterns of disease and treatment. An. Surg. 2009; 249: 210−217.
4. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J. Gastroenterol.2014;20: 2482–91.
5. Grzegorz Mizerski, Magdalena Dziurzyńsk, Andrzej Jaroszyński Wpływ postaci metforminy na częstość występowania objawów niepożądanych, Forum Medycyny Rodzinnej 2015;9(2):136-138.
6. Gwee K, Ghoshal U, Chen M. Irritable bowel syndrome in Asia: pathogenesis, natural history, epidemiology and management. J Gastroenterol Hepatol 2018; 33: 99-110
7. Husby S., Koletzko S., Korponay-Szabo I. i wsp. European Society for Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for diagnosing coeliac disease 2020 Journal of Pediatric Gastroenterology and Nutrition, 2020; 70 (1): 141–156
8. Interna. Medycyna Praktyczna, Kraków 2022
9. J.F. Ludvigsson, J.C. Bai, F. Biagi, T.R. Card, C. i współpr. Authors of the BSG Coeliac Disease Guidelines Development Group: Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut, 2014; 63: 1210–1228
10. Jacek Czepiel 1, Mirosław Dróżdż 2, Hanna Pituch 3, Ed J Kuijper 4 5, William Perucki 6, Aleksandra Mielimonka 7, Sarah Goldman 7, Dorota Wultańska 3, Aleksander Garlicki 8, Grażyna Biesiada 9 Clostridium difficile infection: review PMID: 30945014 PMCID: PMC6570665
11. Katarzyna Nabrdalik1,2, Karolina Skonieczna-Z˙ ydecka 3 *, Krzysztof Irlik 4 , Mirela Hendel 4 , Hanna Kwiendacz1 , Igor Łoniewski 3 , Kornelia Januszkiewicz 3 , Janusz Gumprecht 1 and Gregory Y. H. Lip2, Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. Front Endocrinol (Lausanne). 2022 Sep 14;13:975912.
12. Khan A, Suarez MG, Murray JA. Nonceliac gluten and wheat sensitivity. Clin Gastroenterol Hepatol 2019 Apr 10
13. Maciej Gonciarz, Dawid Szkudłapski, Aldona Mularczyk, Piotr Radwan, Maria Kłopocka, Witold Bartnik, Grażyna Rydzewska Wytyczne postępowania z chorymi na nieswoiste choroby zapalne jelit w praktyce lekarza rodzinnego (2017)
14. MetaHIT consortium, Forslund K., Hildebrand F., Nielsen T. i wsp.: Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528: 262–266.
15. Nguyen G.C, Steinhart A.H. Nationwide patterns of hospitalizations to centers with high volume of admissions for infammatory bowel discease and their impact on mortality. Infamm. Bowel. Dis. 2008; 14: 1688−1694.
16. Pancreatitis: TIGAR-O Version 2 Risk/Etiology Checklist With Topic Reviews, Updates, and Use Primers, David C Whitcomb 1; North American Pancreatitis Study Group, PMID: 31166201 PMCID: PMC6613863
17. Pietrzak A., Skrzydło-Radomańska B., Mulak A., Lipiński M., Małecka-Panas E., Reguła J., Rydzewska G. Guidelines on the management of irritable bowel syndrome. Gastroenterology Rev 2018; 13 (4): 167–196.
18. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506
19. Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020 Oct;159(4):1526-1532.
20. Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging. 1998 Sep;13(3):245-53.
21. Rodriguez J., Hiel S., Delzenne N.M.: Metformin: old friend, new ways of action-implication of the gut microbiome? Curr. Opin. Clin. Nutr. Metab. Care 2018; 21, 294–301.
22. S. Miehlke, D. Guagnozzi, Y. Zabana, G.E. Tontini, A.-M. i współpr.: European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations  United European Gastroenterology Journal, 2021; 9: 13–37
23. Sciarretta G, Fagioli G, Furno A, et al. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut. 1987;28:970–5.
24. Small Intestinal Bacterial Overgrowth: How to Diagnose and Treat (and Then Treat Again) Brian Ginnebaugh 1, William D Chey 2, Richard Saad 2 PMID: 32718571
25. Stange EF, Travis SP, Vermeire S i wsp. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23.
26. Tursi A., Brandimarte G., Elisei W. i wsp. Fecal calprotectin in colonic diverticular disease: a case-control study. Int. J. Colorectal Dis. 2009; 24: 49−55.
27. Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management. Misselwitz B, Butter M, Verbeke K, Fox MR.Gut. 2019 Nov;68(11):2080-2091
28. Will Takakura 1, Mark Pimentel 2 3, Satish Rao 4, A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth Am J Gastroenterol, 2022 Mar 1;117(3):470-477

Dieta

1. Cohen S.A. i wsp., Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease, J Pediatr Gastroenterol Nutr., 2014
2. Grzymisławski M. (red), Dietetyka kliniczna, Wydanie I, Warszawa, PZWL, 2019

3. Halmos E. i wsp., Diets That Differ in Their FODMAP Content Alter the Colonic Luminal Microenviroment, Gut, 2015
4. Halmos E., A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome, Gastroenterology, 2013
5. http://www.tlustezycie.pl/2013/06/fazy-diety-eliminacyjnej-scd.html, dostęp: 15 czerwca 2022 r.
6. https://dietetycy.org.pl/dieta-scd/, dostęp: 15 czerwca 2022 r.
7. https://digestivehealthinstitute.org/fast-tract-diet-qa/, dostęp: 30.08.2022
8. https://www.gidoctor.net/contents/diet-for-ibs-and-sibo, dostęp: 29.08.2022
9. https://www.naczyniapolaczone.pl/dieta-w-sibo-przeglad/, dostęp: 15 czerwca 2022 r.
10. Niepublikowane materiały szkoleniowe Online FODMAP and IBS Training for Dietetitians, Monash University, 2019

11. O’Dwyer D., Darville R., Specific carbohydrate diet: irritable bowl syndrome patient case study, Nutrition & Food Science, 2015
12. Obih C. i wsp., Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within and academic IBD center, Nutrition, 2016
13. Pimentel M. i wsp., A 14-Days Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test, Digestive Disases and Sciences, 2004
14. Stachowska E. (red), Żywienie w zaburzeniach mikrobioty jelitowej, Wydanie I, Warszawa, PZWL, 2021
15. Suskind D. L. i wsp., Nutritional Therapy in Pediatric Crohn Disease: The Specific Carbohydrate Diet, Journal of pediatric gastroenterology and nutrition, 2013
16. Suskind D.L. i wsp., Patients Perceive Clinical Benefit with the Specific Carbohydrate Diet for Inflammatory Bowel Disease, Digestive Diseases and Sciences, 2016
17. Vincenzi M. i wsp., Effects of a low FODMAP diet and specific carbohydrate diet on symptoms and nutritional adequacy of patients with irritable bowel syndrome: Preliminary results of a single-blinded randomized trial, Journal of Translational Internal Medicine, 2017
18. Wielgosz-Grochowska J., Domanski N., Drywień E., Efficacy of an Irritable Bowel Syndrome Diet in the Treatment of Small Intestinal Bacterial Overgrowth: A Narrative Review, Nutrietnts, 2022

Suplementacja

1. Ammonis M.C. i wsp., Lactoferrin: A bioinspired, anti-biofilm therapeutic, Biofouling., 2013
2. Belapurkar P. i wsp., Immunomodulatory effects of triphala and its individual constituents: a review, Indian J Pharm Sci., 2014

3. Chedid V. i wsp., Herbal therapy is equivalent of rifaximin for the treatment of small intestinal bacterial overgrowth, Global Advanced in Health and Medicine, 2014
4. Chen C. i wsp., A Randomised Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea – Predominant Irritable Bowel Syndrome, Phytoter Res. Nov, 2015
5. Furnari M., i wsp., Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth, Aliment Pharmacol Ther. 2010
6. https://dietetycy.org.pl/dieta-scd/, dostęp: 15 czerwca 2022 r.
7. https://mir.gdynia.pl/ocena-narazenia-konsumentow-ryb-na-szkodliwe-dzialanie-zanieczyszczen; dostęp 26 października 2022
8. Januszko O., Kałuża J., Znaczenie ryb i przetworów rybnych w żywieniu człowieka – analiza korzyści i zagrożeń, Kosmos, Problemy Nauk Biologicznych, tom 68, nr 2, 2019
9. Jańczyk W., Socha P., Kliniczne efekty suplementacji wielonienasyconymi kwasami omega-3, Standardy Med. Pediatria, 2009
10. Kaczmarczyk-Sedlak I., Ciołkowski A., Zioła w medycynie. Choroby układu pokarmowego, PZWL, 2020
11. Kania M., Baraniak J., Właściwości lecznicze roślin przyprawowych na przykładzie ostryżu długiego, Post. Fitoter., nr 16, 2015
12. Khalighi A. i wsp., Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)-a pilot study, Indian J Med Res., 2014
13. Kuczyńska B. i wsp., Krótkołańcuchowe kwasy tłuszczowe – mechanizm działania, potencjalne zastosowanie kliniczne oraz zalecenia dietetyczne, Nowiny Lekarskie, 2011
14. Lamer-Zarawska E. (red.), Fitoterapia i leki roślinne, PZWL, 2014

15. Leventogiannis K. i wsp., Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth, Probiotics Antimicrob Proteins., 2019
16. Lopresti A. i wsp., Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study, BMC Cpmpleted Med Ther., 2021
17. Malm A. (red.), Olejki eteryczne w profilaktyce i leczeniu chorób infekcyjnych, PZWL, 2021
18. Mania M., Wojciechowska-Mazurek M., Starska K., Rebeniak M., Postupolski J., Ryby i owoce morza jako źródło narażenia człowieka na metylortęć, Rocz.Panstw. Zakł. Hig., nr 63, 2012
19. Materac E., Marczyński Z., Bodek K.H., Rola kwasów tłuszczowych omega-3 i omega-6 w organizmie człowieka, Bromatologia. Chemia. Toksykologia, XLVI, 2013
20. McRorie Jr J., McKeown N., Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber, J Acad Nutr Diet., 2017
21. Przybylska S., Kurkumina-prozdrowotny barwnik kurkumy, Probl.Hig.Epidemiol., nr 96, 2015
22. Sikander A. i wsp., Role of serotonin in gastrointestinal motility and irritable bowel syndrome, Clin Chim Acta., 2009
23. Soifer L. O.i wsp., Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: a pilot study, Acta Gastroenterol Latinoam., 2010
24. Szewczyk P. i wsp., Melatonina – metabolizm i rola hormone szyszynki, Pielęgniarstwo i Zdrowie Publiczne, 2018
25. Urbańczyk-Lipkowska Z., Kurkumina-nadzieja w prewencji i leczeniu chorób neurodegeneracyjnych, GF, 2014

26. Vendrame S. i wsp., Six-week consumption of a wild blueberry powder drink incrases bifidobacteria in the human gut, J Agric Food Chem., 2011
27. Wielgosz-Grochowska J., Domanski N., Drywień E., Efficacy of an Irritable Bowel Syndrome Diet in the Treatment of Small Intestinal Bacterial Overgrowth: A Narrative Review, Nutrietnts, 2022
28. Wierońska J., Kurkuma-roślinne panaceum, Wszechświat, t. 118, nr 4-6, -2017
29. Zhong Ch. i wsp, Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence, J Clin Gastroenterol., 2017

Terapia wiscelarna

1. Bochenek A., Reicher M., Anatomia prawidłowa człowieka, t.II, PZWL, Warszawa, 2011.
2. Stone C. A., Osteoaptia wisceralna i położnicza, MedPharm, Wrocław, 2021.
3. Kocjan, J.; Adamek, M.; Gzik-Zroska, B.; Czyżewski, D.; Rydel, M. „Sieć Oddechowa”. Wielofunkcyjna Rola Przepony—Przegląd Piśmiennictwa. Adv. Respir. Med. 2017, 85, 29-38. https://doi.org/10.5603/ARM.57076
4. Sliwka A, Pilinski R, Rosa W, Nowobilski R. The influence of the trunk muscle activation on occlusion pressure and respiratory muscle strength in healthy participants: Randomized controlled trial. Respir Physiol Neurobiol. 2021 Aug;290:103682. doi: 10.1016/j.resp.2021.103682. Epub 2021 May 10. PMID: 33979696.
5. Rao SSC, Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin Transl Gastroenterol. 2019;10(10):e00078. doi:10.14309/ctg.0000000000000078
6. Petrone P, Sarkisyan G, Coloma E, Akopian G, Ortega A, Kaufman HS. Small Intestinal Bacterial Overgrowth in Patients With Lower Gastrointestinal Symptoms and a History of Previous Abdominal Surgery. Arch Surg. 2011;146(4):444–447. doi:10.1001/archsurg.2011.55
7. Kim DB, Paik CN, Kim YJ, et al. Positive Glucose Breath Tests in Patients with Hysterectomy, Gastrectomy, and Cholecystectomy. Gut Liver. 2017;11(2):237-242. doi:10.5009/gnl16132
8. Daniluk J., Przewlekłe zaparcia — niedoceniany problem kliniczny, Gastroenterologia Kliniczna 2018, tom 10, nr 1: 1–13
9. De Schryver AM, Keulemans YC, Peters HP, et al. Effects of regularphysical activity on defecation pattern in middle-aged patients complaining of chronic constipation. Scand J Gastroenterol. 2005; 40(4):422–429, indexed in Pubmed: 16028436.
10. McKeown P., Tlenowa przewaga. Trenuj efektywnie, popraw wydolność, wzmocnij zdrowie, Galaktyka, 2017.
11. Iovino P, Bucci C, Tremolaterra F, Santonicola A, Chiarioni G. Bloating and functional gastro-intestinal disorders: where are we and where are we going?. World J Gastroenterol. 2014;20(39):14407-14419. doi:10.3748/wjg.v20.i39.14407
12. Dainese R, Serra J, Azpiroz F, Malagelada JR. Influence of body posture on intestinal transit of gas. Gut. 2003;52(7):971-974. doi:10.1136/gut.52.7.971
13. Villoria A, Serra J, Azpiroz F, Malagelada JR. Physical activity and intestinal gas clearance in patients with bloating. Am J Gastroenterol. 2006 Nov;101(11):2552-7. doi: 10.1111/j.1572-0241.2006.00873.x. Epub 2006 Oct 4. PMID: 17029608.
14. Johannesson E, Ringstrom G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015;21:600–8
15. Hosseini-Asl MK, Taherifard E, Mousavi MR. The effect of a short-term physical activity after meals on gastrointestinal symptoms in individuals with functional abdominal bloating: a randomized clinical trial. Gastroenterol Hepatol Bed Bench. 2021;14(1):59-66.
16. Marlicz W., The effect of physical activity and exercise on gut microbiota – the role of probiotics in the sports nutrition, Forum Zaburzeń Metabolicznych 2014, tom 5, nr 3, 129–140.
17. Lassmann, Ł.; Pollis, M.; Żółtowska, A.; Manfredini, D. Gut Bless Your Pain—Roles of the Gut Microbiota, Sleep, and Melatonin in Chronic Orofacial Pain and Depression. Biomedicines 2022, 10,1528. https://doi.org/10.3390/biomedicines10071528
18. Gallotta S, Bruno V, Catapano S, Mobilio N, Ciacci C, Iovino P. High risk of temporomandibular disorder in irritable bowel syndrome: Is there a correlation with greater illness severity?. World J Gastroenterol. 2017;23(1):103-109. doi:10.3748/wjg.v23.i1.103
19. Silverthorn D.U., Fizjologia człowieka. Zintegrowane podejście, PZWL, 2019.
20. Habib N., Jak właściwie stymulować nerw błędny, Vital, 2021.